Caffeine in the management of patients with headache

Table 2 Pooled results from 2 TTH trials in patients over 4 h for AAC-130, APAP, and placebo [74]

Measure	AAC-130 (n = 1369)	APAP (n = 1376)	Placebo (n = 689)
SPID	5.30 ± 0.06^a,b	4.70 ± 0.07^b	3.95 ± 0.10
%SPID	57.6 ± 0.7^a,b	50.6 ± 0.7^b	42.7 ± 1.0
Maximum PID	1.89 ± 0.02^a,b	1.74 ± 0.02^b	1.53 ± 0.03
TOTPAR	10.52 ± 0.10^a,b	9.38 ± 0.10^b	8.20 ± 0.16
Maximum PAR	3.42 ± 0.02^a,b	3.14 ± 0.03^b	2.81 ± 0.04
Time to pain at least half gone (hours)	3.01 ± 0.03^a,b	2.73 ± 0.03^b	2.38 ± 0.05

AAC-130, acetaminophen 500 mg, aspirin 500 mg, and caffeine 130 mg per 2-tablet dose; APAP, acetaminophen 1000 mg per 2-tablet dose; SPID, sum of pain intensity differences; PID, pain intensity difference from baseline; TOTAR, total pain relief; PAR, pain relief
Values are mean ± standard error
^a P < 0.05 vs APAP
^b P < 0.05 vs placebo

ISSN: 1129-2377